중재적 종양학 시장 : 시장 규모, 점유율, 성장률, 산업 분석, 유형별, 용도별, 지역별 고찰 및 예측(2026-2034년)

Growth Factors of interventional oncology Market

The global interventional oncology market is experiencing consistent growth due to the rising global cancer burden and increasing preference for minimally invasive cancer treatment procedures. In 2025, the global interventional oncology market was valued at USD 2.34 billion. The market is projected to grow from USD 2.53 billion in 2026 and reach USD 4.77 billion by 2034, registering a CAGR of 8.25% during the forecast period (2026-2034).

North America dominated the global interventional oncology market with a 42.20% market share in 2025, driven by advanced healthcare infrastructure, high cancer prevalence, and early adoption of image-guided minimally invasive oncology procedures.

Interventional oncology involves the diagnosis, treatment, and palliation of cancer using image-guided, minimally invasive techniques, including ablation, embolization, and radiation-based therapies. These procedures offer benefits such as reduced hospital stays, lower complication risks, and faster recovery, making them increasingly preferred over conventional open surgeries.

Impact of COVID-19 on the Market

The interventional oncology market witnessed a temporary decline during the COVID-19 pandemic due to lockdown restrictions, postponed cancer treatments, and reduced hospital visits. Many elective oncology procedures were delayed in 2020, negatively impacting procedural volumes.

However, with the lifting of restrictions, hospital visits for cancer diagnosis and treatment increased significantly in 2021, compensating for the delayed procedures. As a result, the market regained momentum and is expected to witness steady growth throughout the forecast period.

Market Trends

Growing Adoption of Radioembolization

One of the most prominent trends in the interventional oncology market is the increasing adoption of radioembolization. This minimally invasive technique delivers radioactive microspheres directly to tumor-feeding blood vessels, offering targeted tumor destruction with minimal damage to surrounding tissues.

Originally developed for liver cancer, radioembolization is now being explored for colorectal cancer and neuroendocrine tumors. In June 2022, research published by the Radiological Society of North America reported a 15-month survival rate in patients undergoing transarterial radioembolization for metastatic colorectal cancer, further supporting its clinical adoption.

Market Growth Drivers

Rising Global Cancer Prevalence

The increasing prevalence of cancer is a major driver of market growth. According to the World Health Organization (WHO), there were approximately 20 million new cancer cases and 9.7 million cancer-related deaths globally in 2020. Common cancers such as liver, lung, breast, and kidney cancers continue to drive demand for effective treatment solutions.

Shift Toward Minimally Invasive Procedures

Patients and healthcare providers are increasingly preferring minimally invasive surgical (MIS) procedures due to advantages such as reduced pain, shorter hospital stays, faster recovery, and lower complication rates. Studies have shown that patients undergoing MIS procedures experience fewer complications compared to open surgery, encouraging wider adoption of interventional oncology techniques.

Market Restraints

Despite strong growth potential, the market faces challenges related to the high cost of interventional oncology procedures and devices. Advanced imaging systems, embolization devices, and ablation technologies require significant capital investment. Additionally, the shortage of trained interventional oncologists, especially in developing regions, limits market penetration and patient access to advanced treatments.

Segmentation Analysis

By Type

Radiation therapy devices dominated the market with a 49.48% share in 2026, supported by rising cancer-related hospitalizations. Embolization devices are expected to register the highest CAGR due to their precision and effectiveness.

By Cancer Type

The liver cancer segment held the largest market share at 59.70% in 2026, driven by high adoption of embolization and ablation therapies.

By End User

Hospitals dominated the market with a 67.34% share in 2026, owing to increasing patient admissions and availability of advanced treatment infrastructure.

Regional Insights

• North America: Market value reached USD 0.99 billion in 2025; the U.S. market is projected to reach USD 1.0 billion by 2026.
• Europe: Growth supported by rising lung cancer prevalence and improved healthcare infrastructure.
• Asia Pacific: Expected to grow at the highest CAGR due to infrastructure development and increasing device launches in China, Japan, and India.

Key Industry Players

Major companies include Boston Scientific Corporation, Siemens Healthineers, Terumo Corporation, Merit Medical Systems, BD, and AngioDynamics. Product innovation and regulatory approvals remain key growth strategies.

Conclusion

The global interventional oncology market is set to witness robust growth, expanding from USD 2.34 billion in 2025 to USD 4.77 billion by 2034. Rising cancer prevalence, growing preference for minimally invasive procedures, and continuous technological advancements are driving market expansion. Although high treatment costs and limited availability of skilled professionals pose challenges, increasing investments in healthcare infrastructure and innovation are expected to support sustained market growth during the forecast period.

Segmentation By Type

• Radiation Therapy Devices
• Ablation Devices
  • Microwave ablation
  • Radiofrequency ablation
  • Cryoablation
  • Others
• Embolization Devices
  • Microcatheters
  • Guidewires

By Cancer Type

• Lung Cancer
• Liver Cancer
• Kidney Cancer
• Others

By End-User

• Hospitals
• Specialty Clinics
• Others

By Geography

• North America (By Type, Cancer Type, End-user, and Country)
  • U.S. (By Cancer Type)
  • Canada (By Cancer Type)
• Europe (By Type, Cancer Type, End-user, and Country/Sub-region)
  • U.K. (By Cancer Type)
  • Germany (By Cancer Type)
  • France (By Cancer Type)
  • Spain (By Cancer Type)
  • Italy (By Cancer Type)
  • Rest of Europe (By Cancer Type)
• Asia Pacific (By Type, Cancer Type, End-user, and Country/Sub-region)
  • Japan (By Cancer Type)
  • China (By Cancer Type)
  • India (By Cancer Type)
  • Australia (By Cancer Type)
  • Rest of Asia Pacific (By Cancer Type)
• Rest of the World (By Type, Cancer Type, and End-user)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Cancer Diseases, By Key Countries, 2025
• 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships)
• 4.3. Overview: Technological Advancements in Interventional Oncology
• 4.4. Impact of COVID-19 on the Market

5. Global Interventional Oncology Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Radiation Therapy Devices
  • 5.1.2. Ablation Devices
    • 5.1.2.1. Microwave Ablation
    • 5.1.2.2. Radiofrequency Ablation
    • 5.1.2.3. Cryoablation
    • 5.1.2.4. Others
  • 5.1.3. Embolization Devices
    • 5.1.3.1. Microcatheters
    • 5.1.3.2. Guidewires
• 5.2. Market Analysis, Insights and Forecast - By Cancer Type
  • 5.2.1. Lung Cancer
  • 5.2.2. Liver Cancer
  • 5.2.3. Kidney Cancer
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By End-user
  • 5.3.1. Hospitals
  • 5.3.2. Specialty Clinics
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Rest of the World

6. North America Interventional Oncology Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Radiation Therapy Devices
  • 6.1.2. Ablation Devices
    • 6.1.2.1. Microwave Ablation
    • 6.1.2.2. Radiofrequency Ablation
    • 6.1.2.3. Cryoablation
    • 6.1.2.4. Others
  • 6.1.3. Embolization Devices
    • 6.1.3.1. Microcatheters
    • 6.1.3.2. Guidewires
• 6.2. Market Analysis, Insights and Forecast - By Cancer Type
  • 6.2.1. Lung Cancer
  • 6.2.2. Liver Cancer
  • 6.2.3. Kidney Cancer
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By End-user
  • 6.3.1. Hospitals
  • 6.3.2. Specialty Clinics
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
    • 6.4.1.1. By Cancer Type
  • 6.4.2. Canada
    • 6.4.2.1. By Cancer Type

7. Europe Interventional Oncology Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Radiation Therapy Devices
  • 7.1.2. Ablation Devices
    • 7.1.2.1. Microwave Ablation
    • 7.1.2.2. Radiofrequency Ablation
    • 7.1.2.3. Cryoablation
    • 7.1.2.4. Others
  • 7.1.3. Embolization Devices
    • 7.1.3.1. Microcatheters
    • 7.1.3.2. Guidewires
• 7.2. Market Analysis, Insights and Forecast - By Cancer Type
  • 7.2.1. Lung Cancer
  • 7.2.2. Liver Cancer
  • 7.2.3. Kidney Cancer
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By End-user
  • 7.3.1. Hospitals
  • 7.3.2. Specialty Clinics
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. U.K.
    • 7.4.1.1. By Cancer Type
  • 7.4.2. Germany
    • 7.4.2.1. By Cancer Type
  • 7.4.3. France
    • 7.4.3.1. By Cancer Type
  • 7.4.4. Spain
    • 7.4.4.1. By Cancer Type
  • 7.4.5. Italy
    • 7.4.5.1. By Cancer Type
  • 7.4.6. Rest of Europe
    • 7.4.6.1. By Cancer Type

8. Asia Pacific Interventional Oncology Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Radiation Therapy Devices
  • 8.1.2. Ablation Devices
    • 8.1.2.1. Microwave Ablation
    • 8.1.2.2. Radiofrequency Ablation
    • 8.1.2.3. Cryoablation
    • 8.1.2.4. Others
  • 8.1.3. Embolization Devices
    • 8.1.3.1. Microcatheters
    • 8.1.3.2. Guidewires
• 8.2. Market Analysis, Insights and Forecast - By Cancer Type
  • 8.2.1. Lung Cancer
  • 8.2.2. Liver Cancer
  • 8.2.3. Kidney Cancer
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By End-user
  • 8.3.1. Hospitals
  • 8.3.2. Specialty Clinics
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. Japan
    • 8.4.1.1. By Cancer Type
  • 8.4.2. China
    • 8.4.2.1. By Cancer Type
  • 8.4.3. India
    • 8.4.3.1. By Cancer Type
  • 8.4.4. Australia
    • 8.4.4.1. By Cancer Type
  • 8.4.5. Rest of Asia Pacific
    • 8.4.5.1. By Cancer Type

9. Rest of the World Interventional Oncology Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Radiation Therapy Devices
  • 9.1.2. Ablation Devices
    • 9.1.2.1. Microwave Ablation
    • 9.1.2.2. Radiofrequency Ablation
    • 9.1.2.3. Cryoablation
    • 9.1.2.4. Others
  • 9.1.3. Embolization Devices
    • 9.1.3.1. Microcatheters
    • 9.1.3.2. Guidewires
• 9.2. Market Analysis, Insights and Forecast - By Cancer Type
  • 9.2.1. Lung Cancer
  • 9.2.2. Liver Cancer
  • 9.2.3. Kidney Cancer
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By End-user
  • 9.3.1. Hospitals
  • 9.3.2. Specialty Clinics
  • 9.3.3. Others

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. Boston Scientific Corporation
    • 10.2.1.1. Overview
    • 10.2.1.2. Products
    • 10.2.1.3. SWOT Analysis
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. Strategies
    • 10.2.1.6. Financials (Based on Availability)
  • 10.2.2. Merit Medical Systems
    • 10.2.2.1. Overview
    • 10.2.2.2. Products
    • 10.2.2.3. SWOT Analysis
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. Strategies
    • 10.2.2.6. Financials (Based on Availability)
  • 10.2.3. Terumo Corporation
    • 10.2.3.1. Overview
    • 10.2.3.2. Products
    • 10.2.3.3. SWOT Analysis
    • 10.2.3.4. Recent Developments
    • 10.2.3.5. Strategies
    • 10.2.3.6. Financials (Based on Availability)
  • 10.2.4. Siemens Healthcare GmbH
    • 10.2.4.1. Overview
    • 10.2.4.2. Products
    • 10.2.4.3. SWOT Analysis
    • 10.2.4.4. Recent Developments
    • 10.2.4.5. Strategies
    • 10.2.4.6. Financials (Based on Availability)
  • 10.2.5. BD
    • 10.2.5.1. Overview
    • 10.2.5.2. Products
    • 10.2.5.3. SWOT Analysis
    • 10.2.5.4. Recent Developments
    • 10.2.5.5. Strategies
    • 10.2.5.6. Financials (Based on Availability)
  • 10.2.6. AngioDynamics
    • 10.2.6.1. Overview
    • 10.2.6.2. Products
    • 10.2.6.3. SWOT Analysis
    • 10.2.6.4. Recent Developments
    • 10.2.6.5. Strategies
    • 10.2.6.6. Financials (Based on Availability)
  • 10.2.7. Hologic, Inc.
    • 10.2.7.1. Overview
    • 10.2.7.2. Products
    • 10.2.7.3. SWOT Analysis
    • 10.2.7.4. Recent Developments
    • 10.2.7.5. Strategies
    • 10.2.7.6. Financials (Based on Availability)
  • 10.2.8. Teleflex Incorporated
    • 10.2.8.1. Overview
    • 10.2.8.2. Products
    • 10.2.8.3. SWOT Analysis
    • 10.2.8.4. Recent Developments
    • 10.2.8.5. Strategies
    • 10.2.8.6. Financials (Based on Availability)